Basic Information
| LncRNA/CircRNA Name | LINC00511 |
| Synonyms | NA |
| Region | GRCh38_17:72323123-72640472 |
| Ensemble | ENSG00000227036 |
| Refseq | NR_033876 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | Paclitaxel (PTX) | |
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | cervical cancer |
| ICD-0-3 | C53 |
| Methods | RT-qPCR, in vitro knockdown, Western blot etc. |
| Sample | CC cell line HeLa, PTX-resistant Hela/PTX cells |
| Expression Pattern | up-regulated |
| Function Description | High-expression of LINC00511 was found in CC with its close association with the tumor stage, tumor size and lymph node metastasis. After silencing LINC00511 expression, the expression of MRP1, P-GP, Bcl-2, MMP-2 and MMP-9 was decreased, while Bax and cleaved-caspase-3 increased with more CC cells arrested at G1 phase. Furthermore, silencing of LINC00511 could suppress cell resistance to PTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells |
| Pubmed ID | 31180057 |
| Year | 2019 |
| Title | LINC00511 Knockdown Prevents Cervical Cancer Cell Proliferation and Reduces Resistance to Paclitaxel |
External Links
| Links for LINC00511 | GenBank HGNC NONCODE |
| Links for cervical cancer | OMIM COSMIC |